Human Integrin αVβ6 / Latent TGF-β1 Inhibitor Screening Kit (TR-FRET)

• Simple and fast operation - No complicated washing steps, significantly reducing time.
• High batch consistency - Strict control over raw materials and finished product quality, ensuring a stable supply.
• Accurate and reliable results - High sensitivity with minimal matrix effects.
• High throughput capability - Support multiple product specifications, ideal for high-throughput screening.
• Fast completion - Results in just 1.5 hour.

The Human Integrin αVβ6 / Latent TGF-β1 Inhibitor Screening Kit (TR-FRET) is based on a homogeneous (no wash) competition TR-FRET technology (Time-Resolved Fluorescence Resonance Energy Transfer) to screen for inhibitors of human integrin αVβ6 binding to latent TGF-β1 within 1.5 hours. It can also be used as a universal detection tool to identify the ability of human integrin αVβ6 to bind to human latent TGF-β1.

1. Unopened kit should be stored at 2℃-8℃ upon receiving.

2. Find the expiration date on the outside packaging and do not use reagents past their expiration date.

3. The opened kit should be stored per components table. The shelf life is 30 days from the date of opening.

This Human Integrin αVβ6 / Latent TGF-β1 Inhibitor Screening Kit (TR-FRET) is based on TR-FRET technology (Time-Resolved Fluorescence Resonance Energy Transfer). This assay uses the mixture of biotinylated human Latent TGF-β1 and Europium-chelate labeled streptavidin as the Donor and FA Labeled Human Integrin αVβ6 Protein as the Acceptor.

— When the sample does not contain the inhibitors that block the binding of human Integrin αVβ6 to human Latent TGF-β1, the Donor and Acceptor are in close proximity because of the binding of human Integrin αVβ6 and human Latent TGF-β1. Upon Donor excitation with light of a specific wavelength (337 nm), in addition to Donor emission (620 nm), non-radiative transfer of energy occurs between Donor and Acceptor, resulting in Acceptor emission (665 nm).

— When the sample contains the inhibitors that block the binding of human Integrin αVβ6 to human Latent TGF-β1, the components inhibit the binding between the Donor and Acceptor and thereby prevent FRET from occurring.